Advanced therapies


Advanced therapies include gene therapy, somatic cell therapy, and tissue engineering. The European Commission proposed regulation of these innovative therapies. Regulation is beneficial for rare disease patients.
Eurordis responded to a public consultation on the Regulation, expressing support for most of the proposed provisions. Eurordis’ reservations included concerns about the proposed Risk Management System, and a fear that the system may generate too many additional regulatory constraints. The regulation was adopted by the European Parliament on 25 April 2007.
Read press release following adoption of the Regulation - April 2007 >
Read European Patients’ Statement of April 2007 >
Read Call to MEPs to support the compromise package (April 2007) >
For more information:
Eurordis' newsletter article "Two EURORDIS representatives appointed to the Committee for Advanced Therapies" (April 2009)
Eurordis’ newsletter article - March 2006


The voice of rare disease patients in EuropeEURORDIS The international voice of people living with rare diseasesRare Disease International Bringing together patients, families and experts to share experiences in a moderated multi-language forum. RareConnect The Rare Barometer Programme is a EURORDIS initiative that carries out surveys to transform rare disease patients' experiences into figures and facts that can be shared with decision-makers.Rare Barometer An international awareness raising campaign taking place on the last day of February each year, Rare Disease Day is a EURORDIS initiativeRare Disease Day Join the largest gathering of rare disease stakeholders across Europe, at the biennial European Conference on Rare Diseases and Orphan Products. ECRD is a EURORDIS initiativeEuropean Conference on Rare Diseases